17 studies found for:    GSK1265744
Show Display Options
Rank Status Study
1 Completed A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral;   Drug: GSK1265744 LAP 800mg intramuscular injection;   Drug: GSK1265744 LAP 200mg subcutaneous injection;   Drug: GSK1265744 LAP 200mg intramuscular injection;   Drug: GSK1265744 LAP 400mg intramuscular injection;   Drug: TMC278 LA 1200mg intramuscular injection;   Drug: TMC278 LA 600mg intramuscular injection
2 Completed A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 30 mg oral;   Drug: Midazolam 3 mg oral + GSK1265744 30mg oral;   Drug: GSK1265744 400 mg (200 nm);   Drug: GSK1265744 400 mg (1 micro m);   Drug: GSK1265744 400 mg (5 micro m)
3 Completed Relative Bioavailability Study of GSK1265744 Formulations
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: GSK1265744 Na Salt Tablets;   Drug: GSK1265744 Free Acid Nanomilled Capsules;   Drug: GSK1265744 Free Acid Micronized Capsules
4 Completed A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Reference formulation;   Drug: GSK1265744 New formulation 1;   Drug: GSK1265744 New formulation 2
5 Completed Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744;   Drug: GSK1265744 matching placebo;   Drug: Moxifloxacin
6 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
7 Completed Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
Conditions: HIV Infection;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg oral solution;   Drug: GSK1265744 5 mg tablet
8 Completed An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
Condition: HIV-associated Lipodystrophy Syndrome
Interventions: Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B;   Drug: 150 mg GSK1265744B;   Drug: Placebo
9 Completed Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: GSK1265744;   Drug: Placebo
10 Not yet recruiting Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Drug: GSK1265744 Tablets;   Drug: Injectable GSK1265744;   Drug: Placebo for GSK1265744 Tablets;   Drug: Injectable Placebo for GSK1265744
11 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension
12 Completed A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744
Condition: HIV Infection
Intervention: Drug: GSK1265744
13 Completed A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Rlipivirine;   Drug: GSK1265744
14 Recruiting Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Ethinyl Estadiol;   Drug: Levonorgestrel;   Drug: GSK1265744
15 Completed DDI Study of Etravirine and GSK1265744
Conditions: Healthy Subjects;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1265744
16 Active, not recruiting A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK744;   Drug: GSK744 LA;   Drug: TMC278 LA;   Drug: ABC/3TC;   Drug: RPV
17 Active, not recruiting Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: 744 Tablet;   Drug: 744 LA Injection;   Drug: Placebo Tablet;   Drug: Placebo Injection

Indicates status has not been verified in more than two years